Neutralizing and binding antibodies to interferon beta in patients with multiple sclerosis

A comparison of assay results from three Italian centres

Francesca Bellomi, Placido Bramanti, Maria Trojano, Carolina Scagnolari, Antonella Muto, Edoardo Sessa, Vito La Volpe, Pierluigi Russo, Guido Antonelli

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Interferon (IFN) beta therapy for multiple sclerosis (MS) is associated with the development of binding antibodies (BAbs) and neutralizing antibodies (NAbs) in a percentage of patients. This study investigated the reproducibility of results of two different antibody detection techniques using serum from 100 patients with MS who were receiving IFN beta therapy. Fifty samples were analysed using a commercially available kit-based BAb assay and a further 50 different samples were analysed using a widely used NAb cytopathic effect assay, at three different laboratories. All three centres agreed on the BAb status of all serum samples. However, only 84% agreement was reached on serum NAb status, and there was significant inter-laboratory variation in NAb titre values. Further analysis of these data revealed a correlation between the mean NAb titre and the coefficient of variation of serum samples, indicating greater discordance with higher NAb titres. A significant interlaboratory variation in NAb titres does exist; thus, caution is required when comparing titres from different centres. It is clear that validated detection assays are needed to accurately quantify NAb titres.

Original languageEnglish
Pages (from-to)40-50
Number of pages11
JournalJournal of Immunoassay and Immunochemistry
Volume30
Issue number1
DOIs
Publication statusPublished - Jan 2009

Fingerprint

Interferon-beta
Neutralizing Antibodies
Multiple Sclerosis
Assays
Antibodies
Serum
Reproducibility of Results
Therapeutics

Keywords

  • Antibodies to interferon
  • Interferon beta
  • Multiple sclerosis

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Clinical Biochemistry
  • Medical Laboratory Technology

Cite this

Neutralizing and binding antibodies to interferon beta in patients with multiple sclerosis : A comparison of assay results from three Italian centres. / Bellomi, Francesca; Bramanti, Placido; Trojano, Maria; Scagnolari, Carolina; Muto, Antonella; Sessa, Edoardo; Volpe, Vito La; Russo, Pierluigi; Antonelli, Guido.

In: Journal of Immunoassay and Immunochemistry, Vol. 30, No. 1, 01.2009, p. 40-50.

Research output: Contribution to journalArticle

Bellomi, Francesca ; Bramanti, Placido ; Trojano, Maria ; Scagnolari, Carolina ; Muto, Antonella ; Sessa, Edoardo ; Volpe, Vito La ; Russo, Pierluigi ; Antonelli, Guido. / Neutralizing and binding antibodies to interferon beta in patients with multiple sclerosis : A comparison of assay results from three Italian centres. In: Journal of Immunoassay and Immunochemistry. 2009 ; Vol. 30, No. 1. pp. 40-50.
@article{3abb03bc8b2f4eac97550a7f8eece329,
title = "Neutralizing and binding antibodies to interferon beta in patients with multiple sclerosis: A comparison of assay results from three Italian centres",
abstract = "Interferon (IFN) beta therapy for multiple sclerosis (MS) is associated with the development of binding antibodies (BAbs) and neutralizing antibodies (NAbs) in a percentage of patients. This study investigated the reproducibility of results of two different antibody detection techniques using serum from 100 patients with MS who were receiving IFN beta therapy. Fifty samples were analysed using a commercially available kit-based BAb assay and a further 50 different samples were analysed using a widely used NAb cytopathic effect assay, at three different laboratories. All three centres agreed on the BAb status of all serum samples. However, only 84{\%} agreement was reached on serum NAb status, and there was significant inter-laboratory variation in NAb titre values. Further analysis of these data revealed a correlation between the mean NAb titre and the coefficient of variation of serum samples, indicating greater discordance with higher NAb titres. A significant interlaboratory variation in NAb titres does exist; thus, caution is required when comparing titres from different centres. It is clear that validated detection assays are needed to accurately quantify NAb titres.",
keywords = "Antibodies to interferon, Interferon beta, Multiple sclerosis",
author = "Francesca Bellomi and Placido Bramanti and Maria Trojano and Carolina Scagnolari and Antonella Muto and Edoardo Sessa and Volpe, {Vito La} and Pierluigi Russo and Guido Antonelli",
year = "2009",
month = "1",
doi = "10.1080/15321810802569857",
language = "English",
volume = "30",
pages = "40--50",
journal = "Journal of Immunoassay and Immunochemistry",
issn = "1532-1819",
publisher = "Taylor and Francis Ltd.",
number = "1",

}

TY - JOUR

T1 - Neutralizing and binding antibodies to interferon beta in patients with multiple sclerosis

T2 - A comparison of assay results from three Italian centres

AU - Bellomi, Francesca

AU - Bramanti, Placido

AU - Trojano, Maria

AU - Scagnolari, Carolina

AU - Muto, Antonella

AU - Sessa, Edoardo

AU - Volpe, Vito La

AU - Russo, Pierluigi

AU - Antonelli, Guido

PY - 2009/1

Y1 - 2009/1

N2 - Interferon (IFN) beta therapy for multiple sclerosis (MS) is associated with the development of binding antibodies (BAbs) and neutralizing antibodies (NAbs) in a percentage of patients. This study investigated the reproducibility of results of two different antibody detection techniques using serum from 100 patients with MS who were receiving IFN beta therapy. Fifty samples were analysed using a commercially available kit-based BAb assay and a further 50 different samples were analysed using a widely used NAb cytopathic effect assay, at three different laboratories. All three centres agreed on the BAb status of all serum samples. However, only 84% agreement was reached on serum NAb status, and there was significant inter-laboratory variation in NAb titre values. Further analysis of these data revealed a correlation between the mean NAb titre and the coefficient of variation of serum samples, indicating greater discordance with higher NAb titres. A significant interlaboratory variation in NAb titres does exist; thus, caution is required when comparing titres from different centres. It is clear that validated detection assays are needed to accurately quantify NAb titres.

AB - Interferon (IFN) beta therapy for multiple sclerosis (MS) is associated with the development of binding antibodies (BAbs) and neutralizing antibodies (NAbs) in a percentage of patients. This study investigated the reproducibility of results of two different antibody detection techniques using serum from 100 patients with MS who were receiving IFN beta therapy. Fifty samples were analysed using a commercially available kit-based BAb assay and a further 50 different samples were analysed using a widely used NAb cytopathic effect assay, at three different laboratories. All three centres agreed on the BAb status of all serum samples. However, only 84% agreement was reached on serum NAb status, and there was significant inter-laboratory variation in NAb titre values. Further analysis of these data revealed a correlation between the mean NAb titre and the coefficient of variation of serum samples, indicating greater discordance with higher NAb titres. A significant interlaboratory variation in NAb titres does exist; thus, caution is required when comparing titres from different centres. It is clear that validated detection assays are needed to accurately quantify NAb titres.

KW - Antibodies to interferon

KW - Interferon beta

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=58149149644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149149644&partnerID=8YFLogxK

U2 - 10.1080/15321810802569857

DO - 10.1080/15321810802569857

M3 - Article

VL - 30

SP - 40

EP - 50

JO - Journal of Immunoassay and Immunochemistry

JF - Journal of Immunoassay and Immunochemistry

SN - 1532-1819

IS - 1

ER -